Results 31 to 40 of about 5,702,542 (372)
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, 2019 BACKGROUND Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T‐cell therapy that targets B‐cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS In this phase 1 study involving patients with
N. Raje +22 more
semanticscholar +1 more source
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
Blood Advances, 2020 Key Points We report the first case of coronavirus disease 2019 (COVID-19) in a multiple myeloma patient successfully treated with tocilizumab. Although tocilizumab was effective in the treatment of COVID-19 in this case, randomized controlled trials are
Xuhan Zhang +7 more
semanticscholar +1 more source
Multi-scale Regional Attention Deeplab3+: Multiple Myeloma Plasma Cells Segmentation in Microscopic Images [PDF]
arXiv, 2021 Multiple myeloma cancer is a type of blood cancer that happens when the growth of abnormal plasma cells becomes out of control in the bone marrow. There are various ways to diagnose multiple myeloma in bone marrow such as complete blood count test (CBC) or counting myeloma plasma cell in aspirate slide images using manual visualization or through image
arxiv
Multiple Myeloma Cancer Cell Instance Segmentation [PDF]
arXiv, 2021 Images remain the largest data source in the field of healthcare. But at the same time, they are the most difficult to analyze. More than often, these images are analyzed by human experts such as pathologists and physicians. But due to considerable variation in pathology and the potential fatigue of human experts, an automated solution is much needed ...
arxiv
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Cancers, 2020 Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting.
S. Ito
semanticscholar +1 more source
Prognostic and predictive biomarker developments in multiple myeloma
Journal of Hematology & Oncology, 2021 New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individual risk factors or disease characteristics ...
C. Wallington-Beddoe, Rachel L. Mynott
semanticscholar +1 more source
Blood Cancer Journal, 2022 Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias.
Kevin Charles Miller +10 more
doaj +1 more source
Determining Optimal Combination Regimens for Patients with Multiple Myeloma [PDF]
arXiv, 2022 While many novel therapies have been approved in recent years for treating patients with multiple myeloma, there is still no established curative regimen, especially for patients with high risk disease. In this work, we use a mathematical modeling approach to determine combination therapy regimens that maximize healthy lifespan for patients with ...
arxiv
Multiple myeloma current treatment algorithms
Blood Cancer Journal, 2020 The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy.
S. Rajkumar, Shaji K. Kumar
semanticscholar +1 more source
Hematology, 2002 AbstractThis update provides new insights into the biology, diagnosis, prognosis, and treatment of multiple myeloma (MM) and its complications.In Section I, Drs. John Shaughnessy, Jr., and Bart Barlogie first correlate global gene microarray expression profiling of patient MM samples with normal plasma cells to provide the basis for a developmental ...
Kenneth C, Anderson +4 more
openaire +2 more sources